Overview

Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Dexrazoxane may lessen the side effects of chemotherapy. PURPOSE: Randomized phase III trial to compare combination chemotherapy with or without dexrazoxane and with or without high-dose methotrexate in patients with acute lymphoblastic leukemia or advanced lymphoblastic non-Hodgkin's lymphoma.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Children's Oncology Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
6-Mercaptopurine
Asparaginase
Calcium, Dietary
Cortisol succinate
Cytarabine
Dexrazoxane
Doxorubicin
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Leucovorin
Levoleucovorin
Liposomal doxorubicin
Mercaptopurine
Methotrexate
Prednisone
Razoxane
Vincristine
Criteria
DISEASE CHARACTERISTICS: T-cell acute lymphoblastic leukemia (ALL) Registration on current
ALL classification study (POG-9400) required within 6 working days prior to entry DR-, T+
DR-, T- or DR+, T+ eligible if T-cell ALL confirmed at the Johns Hopkins Reference
Laboratory Biopsy-proven diffuse lymphoblastic lymphoma Murphy stage III/IV disease
Registered on ALL classification study (POG-9400)

PATIENT CHARACTERISTICS: Age: Over 12 months to under 22 years for T-ALL Under 22 years for
lymphoma

PRIOR CONCURRENT THERAPY: No prior therapy other than steroids or emergency mediastinal
irradiation in patients with severe respiratory distress from mediastinal disease Steroid
treatment allowed provided that physical examination and complete blood count with
differential were performed immediately prior to beginning steroids and results of both are
known